TPST

TPST

Tempest Therapeutics Inc

Tempest Therapeutics develops small molecule therapeutics focused on cancer treatment. Its lead products include Amezalpat for liver cancer and TPST-1495 targeting various cancers. The company collaborates with F. Hoffmann-La Roche for clinical development.

โš•๏ธ Healthcare NASDAQ Listed 2012 $ USD
$1,000 invested 10 years ago โ†’$0today

Score Overview

1 Year
Scoreโ€”
Net Growth-64.11%
Net TrendShrank
Net Income Consistencyโ€”
Rev Growthโ€”
Rev TrendShrank
Revenue Consistencyโ€”
5 Years
Scoreโ€”
Net Growth-52.28%
Net Trend40%
Net Income Consistencyโ€”
Rev Growthโ€”
Rev TrendNever
Revenue Consistencyโ€”
10 Years
Score
Net Growth47.61%
Net Trend40%
Net Income Consistency
Rev Growth-100.00%
Rev TrendNever
Revenue Consistency
All Time
Scoreโ€”
Net Growth-219.01%
Net Trend29%
Net Income Consistency
Rev Growthโ€”
Rev Trend11%
Revenue Consistency

See the full market ranking โ†’

Tempest Therapeutics Inc fundamental performance

Between 2015 and 2025, revenue declined from $ 277K to $ 0.00 and net income went from -$ 73M to -$ 26M. Revenue increased in 0 of those 10 years; net income in 4.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-08-12
$ 1.21โ€”
1 Year2025-08-12
$ 8.81-86.27%
5 Years2021-08-12
$ 178.49-99.32%
10 Years2016-08-12
$ 18.54K-99.99%
All Time2012-11-12
$ 21.94K-99.99%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Year
2026$ 0.00-$ 43M$ 1M
2025$ 0.00-$ 26M$ 7M
2024$ 0.00-$ 41M$ 30M
2023$ 0.00-$ 29M$ 39M
2022$ 0.00-$ 35M$ 31M
2021$ 0.00-$ 28M$ 51M
2020$ 0.00-$ 19M$ 18M
2019-$ 44M$ 63M
2018-$ 27M$ 77M
2017$ 295K-$ 84M$ 67M
2016$ 653K-$ 82M$ 114M
2015$ 277K-$ 73M$ 126M
2014$ 9M-$ 49M$ 60M
2013-$ 29M$ 44M
IPO2012-$ 13M$ 31M

Explore beyond TPST

You're looking at Tempest Therapeutics Inc. Members apply the same fundamental framework across all 3,860 companies we cover.

$99/year $149 founding price

Unlock Holder Dashboard

30-day money-back guarantee.

Explore other companies